Photo by Austin Distel on Unsplash
Katogen BoardMemos™Board-ready regulatory, business development, intellectual property, and payer due diligence - delivered as complete, operator-grade reports created in minutes.
The only operator-encoded due-diligence assessment that reads like a 35-year veteran's private memo to the board - complete with dataroom checklists, critical-path timelines, differentiation scenarios, strategic options, and explicit licensing recommendations.
No junior analysts. No six-figure consulting invoice. Just elite intelligence that accelerates term sheets and IND filings.
Free sample BoardMemo (PDF)
One full illustrative memo — not personalized advice. Opens in a new tab. For hero screenshots, use a page with primary-source citations or the sources appendix, not the cover only.
Most board and licensing diligence still arrives as thin slide packs—or sixty-page consulting binders that take weeks to scope and still lack a single auditable source trail.
BoardMemos are full cross-functional memoranda—regulatory, BD, IP, payer, competitive, and capital-markets depth in one 60–70+ page operator report: executive thesis, ranked strategic options, Decision / Reversibility, dataroom checklists, and a primary-source citations appendix—grounded in 101 official sources plus live filings and trials for your program, delivered in minutes before licensing conversations begin.
Process
How it works
- 1
Input a short brief
Anchor the memo with your program facts, indication priority, and deal context - the same inputs a boutique diligence team would request in week one.
- 2
BoardMemos™ are delivered in minutes
Built on 35+ years of real acquisitions and regulatory judgment - not a generic slide outline. You get narrative depth, ranked options, and explicit commercial significance.
- 3
Download a dataroom-ready PDF
Primary-source citations, Decision / Reversibility sections, strategic options tables, and checklists your team can immediately use.
Differentiation
Why BoardMemos are different
True diligence grade
Executive thesis, artifact checklists, IND critical path, competitive matrix, payer hypotheses, and bull/bear triggers - not a literature review.
Operator scar tissue
Encoded by Doug Drysdale - 17 closed acquisitions, USD 4B+ raised - so the memo reads like a seasoned operator wrote it for the board.
Dataroom-ready today
Structured for how BD, IC, and regulatory affairs teams actually consume diligence - forwardable, quotable, and action-oriented.
Minutes, not months
Replace two to four weeks and roughly USD 20k-75k of traditional boutique or Big-4 scoping for an in-depth 60–70+ page board memorandum in minutes.
Official sources first
Katogen source stack
BoardMemos combine the full primary-source library with live trial, filing, and literature context for your asset—then produce an operator-structured memo with ranked strategic options, evidence gaps, and a primary-source citations appendix.
101 official sources (76 on a refresh schedule · 24 live on every run · 1 biotech issuer filing index) · see full source catalog
FDA & US drugsCRLs, Drugs@FDA, labels, expedited designations, AdCom, inspections, safety comms, and press RSS.
21 sources — show list
- CDC ACIP — vaccine recommendations(CDC)
- DailyMed / drug labeling (openFDA)(FDA)
- DEA — controlled substance scheduling(DEA)
- Drugs@FDA applications (openFDA)(FDA)
- FAERS adverse events (bounded openFDA)(FDA)
- FDA advisory committee calendar(FDA)
- FDA AI / SaMD policy (CDRH)(FDA)
- FDA CDRH — device guidance(FDA)
- FDA complete response letters (openFDA)(FDA)
- FDA drug safety communications(FDA)
- FDA expedited designations (OOPD)(FDA)
- FDA import refusals & alerts(FDA)
- FDA inspections & 483s (openFDA enforcement)(FDA)
- FDA Office of Combination Products(FDA)
- FDA Oncology Center of Excellence(FDA)
- FDA press releases (RSS)(FDA)
- FDA quality & enforcement actions(FDA)
- FDA Sentinel public RWE reports(FDA)
- FDA-related litigation dockets (bounded)(FDA)
- IND critical path operator framing(FDA)
- OHRP — human subjects / Common Rule(OHRP)
TrialsClinicalTrials.gov live API plus EU CTIS index excerpts.
2 sources — show list
SEC & capital marketsEDGAR filings, XBRL, proxies, full-text search, antitrust notices, halts, and EOD quotes.
10 sources — show list
- End-of-day market quotes(Finnhub/Polygon)
- Finnhub — end-of-day market quotes(Finnhub)
- Healthcare antitrust / HSR (Federal Register)(FTC/DOJ)
- NASDAQ trading halts(NASDAQ)
- Polygon.io — end-of-day market quotes (US fallback)(Polygon)
- SEC DEF 14A proxy statements(SEC)
- SEC EDGAR filings index(SEC)
- SEC EDGAR full-text search(SEC)
- SEC primary document excerpts(SEC)
- SEC XBRL company facts(SEC)
Payer & accessCMS coverage & IRA, ICER HTA, EU HTA bundle, AMA CPT, and WHO essential medicines.
9 sources — show list
- AMA CPT / RUC coding policy(AMA)
- CMS Medicare coverage (NCD/LCD)(CMS)
- CMS Medicare drug affordability / IRA(CMS)
- CMS Part D & Medicaid open data(CMS)
- EU HTA guidance index (NICE, HAS, …)(EU)
- HRSA 340B / OPA policy(HRSA)
- ICER value assessments(ICER)
- Medicare Part D payment policy(CMS)
- WHO essential medicines list(WHO)
IP & exclusivityOrange Book, Purple Book, USPTO bulk, PTAB, and EPO legal status.
6 sources — show list
- EPO patent legal status / SPC context(EPO)
- FDA Orange Book (small-molecule exclusivity)(FDA)
- FDA Purple Book (biologics)(FDA)
- USPTO patent bulk index(USPTO)
- USPTO PTAB — proceedings portal(USPTO)
- USPTO PTAB decisions(USPTO)
Global regulators & filingsEMA EPAR, EU safety, ex-US agency indices, SEDAR+, Companies House, and ESMA.
10 sources — show list
- EMA EPAR summaries (English)(EMA)
- EMA PRAC & MHRA drug safety updates(EMA/MHRA)
- EMA quality guidelines (ICH-aligned)(EMA)
- ESMA EU parent issuers(ESMA)
- ICH harmonization guidelines(ICH)
- MHRA — UK medicines regulator(MHRA)
- PMDA, Health Canada, TGA, Swissmedic (English indices)
- SEDAR+ Canada filings index(CSA)
- UK Companies House(UK CH)
- US BIS export control guidance(BIS)
Science & literaturePubMed and preprint ingest; live PubMed, Europe PMC, and preprints on Engine and BoardMemos runs.
2 sources — show list
- bioRxiv / medRxiv preprints (ingest)
- PubMed pivotal publications (ingest)(NIH)
Policy & federal registerFederal Register, Regulations.gov, EUR-Lex pharma package, and thematic EPA surfaces.
6 sources — show list
- EPA facility / site search (supply themes)(EPA)
- EUR-Lex EU pharmaceutical legislation(EU)
- Federal Register documents API(US GPO)
- FTC — health privacy & data security cases(FTC)
- HHS HIPAA & health privacy policy(HHS)
- Regulations.gov dockets API(US GPO)
Pricing
Exceptional Value
Standalone BoardMemo - $1,299
One asset-specific, fully cited, board-ready due-diligence report. Perfect for seed raises, BD outreach, or investor deep-dives.
Purchase BoardMemoAnnual Unlimited - $20,000/year
Billed annually
Unlimited BoardMemos for your entire team, shared folders, custom templates, and priority support. The equivalent of a fractional Chief Strategy Officer on retainer for less than one traditional engagement per quarter.
Contact for Annual UnlimitedSocial proof
What leaders say
“Thank you for this genuinely impressive work, the framework has real depth.”
“Love the report. What I appreciated was the regulatory analysis as well as the capital and market risk analyses.”
Next step